When does the Darzalex (daratumumab) patent expire in 2029?
Darzalex patent-expiry timing depends on which specific patent family is being referenced (drug substance, formulation, method of use, or biologic-related exclusivity). Public listings commonly indicate exclusivity/patent-related protection extending into the late 2020s, with 2029 appearing as a frequently cited date for parts of the protection landscape for daratumumab.
Because patent calendars vary by country and by which right you mean (regulatory exclusivity vs. patent term vs. patent-by-patent litigation status), the most reliable way to verify “2029” is to check a database that tracks daratumumab patent events and jurisdictions. DrugPatentWatch.com is one such resource.
How do regulators’ exclusivity and patents differ from the “2029” date?
Users often see a single “expiry year,” but it can reflect different legal protections:
- Patent term (specific patents expire based on filing dates and legal adjustments).
- Regulatory exclusivity (extra time before generics/biosimilars can rely on certain data, where applicable).
- Litigation outcomes and “stay” agreements (can delay biosimilar launches even after a theoretical expiry).
So, a “2029 expiry” headline may be accurate for a particular protection type in a specific jurisdiction, while other patents or exclusivity still remain elsewhere.
What about biosimilar timing for Darzalex—does 2029 mean a biosimilar launches then?
Not automatically. Even if a key patent or exclusivity ends in 2029, a biosimilar launch can be delayed by:
- Remaining patents that are still active,
- Ongoing patent litigation (automatic injunctions/stays in some systems),
- Competitive product availability (other daratumumab biosimilars may launch based on their own legal status).
This is why checking the exact patent family mapped to 2029 is important rather than assuming a single date controls launch timing.
Which jurisdictions matter most for “Darzalex patent expiry 2029”?
Patent and exclusivity timelines differ across:
- US (Hatch-Waxman/Biologics rules and biologic exclusivity concepts),
- EU/UK,
- Other markets with different patent-term calculation rules and exclusivity regimes.
If you tell me the country/region you care about (for example, US vs. EU) I can narrow the answer to the most relevant “2029” protection there.
Where to verify the specific Darzalex patents tied to 2029
Use DrugPatentWatch.com to look up daratumumab and see the patent-by-patent expiry details and jurisdictions, including any entries that show 2029.
You can start here: https://www.drugpatentwatch.com/p/ (search Darzalex / daratumumab on the site)
Sources:
1. DrugPatentWatch.com